LIMN Key Statistics, Chart & Performance
The current stock price of LIMN is 1.84 USD. In the past month the price increased by 124.36%.
LIMN Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to LIMN.
LIMN Financial Highlights
Over the last trailing twelve months LIMN reported a non-GAAP Earnings per Share(EPS) of -0.2. The EPS increased by 42.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -216.51% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
LIMN Forecast & Estimates
LIMN Ownership
LIMN Latest News, Press Relases and Analysis
LIMN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.39 | 394.886B | ||
| AMGN | AMGEN INC | 17.06 | 206.949B | ||
| GILD | GILEAD SCIENCES INC | 17.1 | 189.204B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.44 | 121.258B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.91 | 82.557B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.99 | 43.353B | ||
| INSM | INSMED INC | N/A | 31.961B | ||
| BIIB | BIOGEN INC | 13.22 | 29.513B | ||
| NTRA | NATERA INC | N/A | 28.022B | ||
| INCY | INCYTE CORP | 13.54 | 21.279B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LIMN
Company Profile
Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company is headquartered in La Palma, California. The company went IPO on 2021-05-18. The firm is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.
Company Info
LIMINATUS PHARMA INC-CL A
6 Centerpointe Dr., #625
La Palma CALIFORNIA US
Employees: 0
Phone: 12132735453
LIMINATUS PHARMA INC-CL A / LIMN FAQ
What does LIMN do?
Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company is headquartered in La Palma, California. The company went IPO on 2021-05-18. The firm is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.
What is the stock price of LIMINATUS PHARMA INC-CL A today?
The current stock price of LIMN is 1.84 USD. The price decreased by -10.24% in the last trading session.
Does LIMN stock pay dividends?
LIMN does not pay a dividend.
What is the ChartMill rating of LIMINATUS PHARMA INC-CL A stock?
LIMN has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the employee count for LIMN stock?
LIMINATUS PHARMA INC-CL A (LIMN) currently has 0 employees.
Can you provide the market cap for LIMINATUS PHARMA INC-CL A?
LIMINATUS PHARMA INC-CL A (LIMN) has a market capitalization of 49.79M USD. This makes LIMN a Nano Cap stock.